Katarina Zimmer, MSci, MS

Katarina Zimmer, MSci, MS, is a science and environmental journalist based in New York. Her work has appeared in The Scientist, National Geographic, Grist, and elsewhere.

All articles by Katarina Zimmer, MSci, MS

Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.

Gastrointestinal Cancers

How Targeted Therapies Could Actually Promote Cancer Cell Mutability

Katarina Zimmer, MSci, MS

January 30, 2020

Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.

The chance of missing a disease-causing variant can be as high as 100% across some groups.

General Oncology

Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities

Katarina Zimmer, MSci, MS

December 17, 2019

The chance of missing a disease-causing variant can be as high as 100% across some groups.

To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.

Multiple Myeloma

Can CAR-T Be Optimized for Multiple Myeloma?

Katarina Zimmer, MSci, MS

November 19, 2019

To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.

Findings underscore the limited generalizability of clinical trial results to patients in the real world.

Renal Cell Carcinoma

Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell Carcinoma

Katarina Zimmer, MSci, MS

November 18, 2019

Findings underscore the limited generalizability of clinical trial results to patients in the real world.

As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.

General Oncology

Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated

Katarina Zimmer, MSci, MS

September 26, 2019

As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.

Are patients who have received fewer prior medications better candidates for the receipt of CAR-T therapies?

Lymphoma

Axi-Cel Moves Toward the First-Line Setting for High-Risk Large B-Cell Lymphoma

Katarina Zimmer, MSci, MS

August 5, 2019

Are patients who have received fewer prior medications better candidates for the receipt of CAR-T therapies?

Next post in Lymphoma

Katarina Zimmer, MSci, MS

All articles by Katarina Zimmer, MSci, MS

How Targeted Therapies Could Actually Promote Cancer Cell Mutability

Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities

Can CAR-T Be Optimized for Multiple Myeloma?

Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell Carcinoma

Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated

Axi-Cel Moves Toward the First-Line Setting for High-Risk Large B-Cell Lymphoma

Germline <i>BRCA2</i> Mutations Linked to Pediatric Lymphomas